TS 01
Alternative Names: mproUK; mutant prourokinase; TS01Latest Information Update: 05 Aug 2026
At a glance
- Originator Beth Israel Deaconess Medical Center; Harvard Medical School
- Developer Thrombolytic Science International
- Class Complement C1 inactivator proteins; Enzyme precursors; Neuroprotectants; Recombinant proteins; Thrombolytics; Vascular disorder therapies
- Mechanism of Action Fibrinolytic agents; Urokinase-type plasminogen activator stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ischaemic stroke
Most Recent Events
- 24 Jul 2026 The Turkish Medicines and Medical Devices Agency (TITCK) authorises to initiate phase II PROMPT-STEMI trial for myocardial infarction
- 24 Jul 2026 Thrombolytic Science International plans a phase II trial for Myocardial infarction in Turkey
- 24 Jul 2026 Thrombolytic Science International plans a phase II trial for Myocardial infarction in Turkey in August 2026